Drug Trial Radar · NCT07034768
A Study to Evaluate EDG-7500 in People With Renal Impairment
Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
37
Actual
Start
Jul 22, 2025
Primary completion
Dec 22, 2025
Study completion Dec 26, 2025
Sponsor
- Lead sponsor
- Edgewise Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of kidney function impairment versus participants with normal kidney function. The safety of EDG-7500 in participants with different levels of kidney function impairment will also be evaluated in this study.
Conditions
- Renal Impairments
Interventions
EDG-7500Drug
Single dose of EDG-7500
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the curve from time zero to last quantifiable concentration (AUC0-last)Time frame: Pre-dose to day 11
- Area under the curve from time zero to extrapolated infinite time (AUC0-inf)Time frame: Pre-dose to day 11
- Maximum observed plasma concentration (Cmax)Time frame: Pre-dose to day 11
- Observed plasma concentration at the end of the dosing interval (C24)Time frame: Pre-dose to day 11
- Time to reach maximum observed plasma concentration (Tmax)Time frame: Pre-dose to day 11
- Plasma elimination half-life (T1/2)Time frame: Pre-dose to day 11
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The University of Miami Division of Clinical Pharmacology
Miami, Florida
Orlando Clinical Research Center
Orlando, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.